• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP).

作者信息

Linden M, Baier D, Beitinger H, Kohnen R, Osterheider M, Philipp M, Reimitz D E, Schaaf B, Weber H J

机构信息

Department of Psychiatry, Free University of Berlin, Germany.

出版信息

Pharmacopsychiatry. 1997 Jan;30(1 Suppl):65-70. doi: 10.1055/s-2007-979520.

DOI:10.1055/s-2007-979520
PMID:9035231
Abstract

The task-force on Phase-IV-Research of the Association for Neuropharmacology and Pharmacopsychiatry (AGNP) has developed guidelines for the implementation of scientifically sound drug utilisation observation studies (DUO studies). These guidelines have been adopted by the executive committee as the position of the association. DUO studies are prospective pharmacoepidemiological studies, by which prescription, illness, and patient data of individual patients are collected without interference with the routine course of treatment. They can answer questions on the interaction of treatment modalities with positive and negative treatment outcome. Scientific standards require that there is a study protocol which describes the epidemiological, statistical, procedural, and quality assurance methodology and states who is responsible for what. As such studies can violate data protection regulations or can be used for sales instead of scientific purposes, consultation of an ethics committee is recommended.

摘要

相似文献

1
Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP).
Pharmacopsychiatry. 1997 Jan;30(1 Suppl):65-70. doi: 10.1055/s-2007-979520.
2
[Guidelines for carrying out application studies in psychopharmacotherapy. "Phase IV Research" Study Group of the Society of Neuropsychopharmacology and Pharmacopsychiatry].[精神药物治疗应用研究指南。神经精神药理学与药物精神病学学会“IV期研究”研究小组]
Nervenarzt. 1994 Sep;65(9):638-44.
3
[The GCP directive--consequences for clinical drug research].[《药物临床试验质量管理规范》指令——对临床药物研究的影响]
Ugeskr Laeger. 2003 Apr 14;165(16):1662-4.
4
Phase IV research and drug utilization observation studies.
Pharmacopsychiatry. 1997 Jan;30(1 Suppl):1-3. doi: 10.1055/s-2007-979510.
5
Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process.
Psychopharmacol Bull. 1993;29(1):51-6.
6
Mortality studies and the effectiveness of drugs in long-term treatment.
Pharmacopsychiatry. 1997 Jan;30(1 Suppl):57-61. doi: 10.1055/s-2007-979518.
7
[Ethics problems in phase IV of drug studies].
Ann Ist Super Sanita. 1998;34(2):203-8.
8
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
9
Guidelines for phase IV clinical trials. Joint Committee on Phase IV Clinical Trial Guidelines.IV期临床试验指南。IV期临床试验指南联合委员会。
Can J Psychiatry. 1994 Dec;39(10):629-33. doi: 10.1177/070674379403901008.
10
[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].[神经精神药理学中的治疗药物监测:AGNP治疗药物监测工作组2017年共识指南摘要]
Nervenarzt. 2019 May;90(5):463-471. doi: 10.1007/s00115-018-0643-9.

引用本文的文献

1
Evaluation of Quality of Life in Children with GH Deficiency and Idiopathic Short Stature Using the Child Behavior Checklist.使用儿童行为量表评估生长激素缺乏症和特发性身材矮小儿童的生活质量
Clin Pediatr Endocrinol. 2009;18(1):15-22. doi: 10.1297/cpe.18.15. Epub 2009 Feb 19.
2
Research ethics. Rethinking research ethics: the case of postmarketing trials.研究伦理。反思研究伦理:上市后试验案例。
Science. 2012 May 4;336(6081):544-5. doi: 10.1126/science.1216086.
3
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.
临床精神药理学中疗效证明的原则标准和问题。
Eur Arch Psychiatry Clin Neurosci. 2010 Feb;260(1):3-16. doi: 10.1007/s00406-009-0071-8.
4
[Psychiatrists and the pharmaceutical industry].[精神科医生与制药行业]
Nervenarzt. 2003 Nov;74(11):955-64. doi: 10.1007/s00115-003-1620-4.